Jay Perry

Jay Perry is an Associate Research Fellow at the University of Wollongong's School of Chemistry and Molecular Bioscience, within the Faculty of Science, Medicine and Health. His research focuses on cutaneous squamous cell carcinoma (cSCC), with expertise in immunotherapy, drug combination strategies, genomic analysis, and tumor biology. He is affiliated with the IHMRI Lab Group.

Research interests include understanding cSCC progression mechanisms, developing therapeutic approaches such as PI3K/CDK inhibitor combinations, and investigating epithelial-mesenchymal transition (EMT). He employs innovative models like tumor spheroids and ex vivo screening to advance clinical translation.

Key contributions include studies on immune checkpoint inhibitors' biomarkers (2024) and sex-based immunotherapy responses (2023). His work spans drug discovery, genomic profiling, and nanotechnology-based therapies.

No scientific awards are listed, but his research has been published in high-impact journals like Journal of Investigative Dermatology and Cancers. He has no listed advisees, and grant details are omitted here. Collaboration with clinical and experimental teams underscores his translational research focus.

Laboratory affiliations include the IHMRI Lab Group, fostering interdisciplinary cancer research.